In December 2022, Novozymes and Chr. Hansen entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies. But what did it take for this to come about?
We are pleased to invite you to this exclusive learning and networking event at Plesner’s for members of DIRF only:
Here we will get insights into the largest merger in Danish history and learn more of what went on behind the scenes – from the initial considerations to the final closing. What considerations were made, which legal aspects came into play and which stakeholders were involved. And what was the role of Investor Relations throughout the process from the first engagement to completion.
This in-person event will take place on May 27 from 9-11am.
Venue: Plesner, Amerika Plads 37, 2100 Copenhagen Ø
Topics include:
- The journey from board room to shareholder support
- Economics and financing
- Regulatory implications
- IR considerations and involvement in the various phases of the process.
All this and much more will be presented by Tobias Björklund, VP, Head of Investor Relations at Novonesis Thomas Holst Laursen & Janus Jepsen, both attornies-at-law and partners at Plesner.
Programme:
9.00 – 9.30: Networking with your peers
9.30 – 10.15: Presentation by Tobias, Thomas and Janus
10.15 – 11.00: General discussion and open Q&A
Most importantly, we hope to have our members engage in an open dialogue in the room with plenty of time for Q&A and discussion of dilemmas along the way – so there will be no recording or streaming of this event.